Literature DB >> 25838877

Atypical early Aspergillus endocarditis post prosthetic mitral valve repair: a case report.

Ahmed AbdulAziz Abuzaid1, Mahmood Zaki2, Habib Tarif1.   

Abstract

A 64-year-old female operated 1 month previous for mitral valve repair presented with acute respiratory distress and dyspnea. Echocardiography showed large echogenic valvular mass measuring 2.3 × 1.3 cm with severe mitral regurgitation and dehiscence of the mitral ring posteriorly. The mass was attached subvalvularly to the ventricular septal-free wall and eroding through it, which required complete aggressive dissection of the infected tissues. Diagnosis was confirmed after resection of the valve by multiple negative blood cultures and positive valvular tissue for Aspergillus fumigatus endocarditis. She was treated with high dose of voriconazole for 3 months. Her postoperative period was complicated by acute-on-chronic renal failure. She responded very well to the management.

Entities:  

Keywords:  Aspergillus endocarditis; Aspergillus fumigates; prosthetic valve endocarditis

Year:  2015        PMID: 25838877      PMCID: PMC4379640          DOI: 10.4103/1995-705X.152999

Source DB:  PubMed          Journal:  Heart Views        ISSN: 1995-705X


INTRODUCTION

Invasive cardiac aspergillosis is a severe and extremely life-threatening disease with a few reported cases.[1] Fungal endocarditis results in echogenic large bulky valvular mass and it may present with acute left ventricular failure (LVF) and dyspnea. The diagnosis needs a high index of suspicion to correlate it with the corresponding echo results in patients who are likely to be infected. We present a case of an atypical early presentation of Aspergillus endocarditis (AE) with an echogenic valvular mass in a previously operated female for mitral valve repair. She was treated successfully with complete resection, valve replacement, and antifungal therapy.

CASE REPORT

A 64-year-old female with multiple comorbidities of diabetes mellitus, hypertension, hypercholesterolemia, renal impairment, and rheumatic mitral valve disease; had recently undergone mitral valve and ascending aortic aneurysm repair electively, a month prior to her presentation. She presented to our emergency department in acute respiratory distress of a few hour's duration. Her preliminary clinical assessment revealed a distressed morbidly obese woman, unable to lie flat with a low oxygen saturation of 47% on room air. Her vital signs on presentation were: Temperature - 37.1°C; pulse - regular, 129 beat/min.; blood pressure (BP) - 130/88 mmHg; and respiratory rate - 35/min. Chest examination showed decreased air entry bilaterally with scattered crepitations and wheezes. Cardiovascular exam showed normal S1, S2 with mitral regurgitation murmur grade 4/6 heard loudest at left midclavicular fifth intercostals space radiating to the axilla. Jugular venous pressure (JVP) was distended. Her peripheries were edematous and cool, but good capillary refill. Abdominal examination was unremarkable. She had no focal neurological deficit. Chest X-ray showed diffuse pulmonary congestion. Electrocardiogram (ECG) showed sinus tachycardia without significant changes. An urgent echocardiography revealed an echogenic mass attached to the posterior leaflet of the mitral valve measuring 2.3 cm × 1.3 cm [Figure 1] with a pulmonary artery pressure of 44 mmHg. The repaired mitral valve was seen in situ with a mean gradient of 12 mmHg with a mild mitral regurgitation. The estimated left ventricular ejection fraction was 60%.
Figure 1

Transthoracic echocardiography (four-chamber view) showing an echogenic mass attached to the posterior leaflet of the mitral valve (MV) measuring 2.3 cm × 1.3 cm

Transthoracic echocardiography (four-chamber view) showing an echogenic mass attached to the posterior leaflet of the mitral valve (MV) measuring 2.3 cm × 1.3 cm Her initial laboratory investigations showed a leukocyte of 26.5 × 109/L, hemoglobin (Hb) - 11.3 g/dl, erythrocyte sedimentation rate (ESR): 75 mm/h, international normalized ratio (INR) - 3.28, urea - 14.4 mmol/l, creatinine: 288 mmol/l, B-type natriuretic peptide (BNP) - 23,300 IU. Multiple sets of blood cultures were sent. The patient was admitted for stabilization and initially managed conservatively as acute pulmonary edema secondary to acute prosthetic mitral valve thrombus. She was managed with antifailure medication and anticoagulation therapy with heparin. Despite therapy, her clinical condition deteriorated with compromising hemodynamics requiring inotropes. A subsequent echocardiography further showed a severe mitral regurgitation jet. A decision for an emergency redo sternotomy and mitral valve replacement was taken. Intraoperative transesophegeal echocardiography confirmed an echogenic mass on the prosthetic mitral valve with severe mitral regurgitation [Figure 2].
Figure 2

Intraoperative transesophegeal echocardiography (color flow Doppler, four-chamber view) showing prosthetic MV repair with severe mitral regurgitation jet

Intraoperative transesophegeal echocardiography (color flow Doppler, four-chamber view) showing prosthetic MV repair with severe mitral regurgitation jet During surgery, the mitral valve was covered by an apparent layer of fibrinous tissue and old thrombi. There was a large mass on the ventricular surface of the mitral valve [Figure 3]. The annuloplasty ring was dehisced from the posterior leaflet annulus. The mass extended all along the posterior leaflet and was infiltrating into the annulus to the ventricular septal free wall. The valve was not suitable for repair. Full debridement was done and the valve was replaced with a CE Magna ease tissue valve, size 27 mm. She was sent back to cardiovascular intensive care unit (CICU) in a stable condition on minimal inotropic support.
Figure 3

Pictograph of mitral annuloplasty ring with remnant vegetation and part of the excised native mitral leaflet

Pictograph of mitral annuloplasty ring with remnant vegetation and part of the excised native mitral leaflet In CICU, empiric antimicrobial therapy (vancomycin and gentamycin) was initiated. A few days later, tissue valve culture report came back as Aspergillus fumigatus. Consequently, therapy was changed to intravenous voriconazole. She had a protracted, prolonged postoperative period complicated with acute on chronic renal failure requiring renal replacement therapy and subsequent upper gastrointestinal bleeding that was treated conservatively with proton pump inhibitors and blood transfusions. She was discharged in reasonably good condition and doing well afterward.

DISCUSSION

Aspergillus is a ubiquitous mold capable of causing several diseases both in healthy humans and immunocompromised hosts. Numerous strands of Aspergillus have been identified. The most commonly responsible species for AE is Aspergillus fumigatus (60–90%).[2] Fungal endocarditis affects approximately 0.1% of all prosthetic valves and the Aspergillus species contributes to approximately 25% of all cases of fungal endocarditis.[3] Prosthetic valve endocarditis (PVE) due to Aspergillus was first reported involving a Starr-Edwards mitral prosthesis[4] and subsequently reported on mechanical prostheses in both the mitral and aortic positions.[5] Numerous risk factors have been identified in the pathogenesis of PVE with the most important being previous valvular surgery.[23] Other risk factors have been incriminated, including malignancy, indwelling central venous catheters, use of broad-spectrum antibiotics, and intravenous drug use.[3] AE is often caused by contamination during heart surgery, which we presume to be the case in this atypical early presentation of AE.[6] The risk being particularly high when extracorporeal circulation is performed[7] and when valve replacement[8] or repair[9] is performed. In this case presentation, the patient had developed early fungal PVE within the 1st month of surgery. This could be related mostly to the preexisting valvular disease or probably the contamination during heart surgery. PVE is categorized based on the temporal relationship of infection to surgery. Early infections occur within 60 days of surgery, while late PVE after 60 days.[10] Fungal PVE can occur early or late, but is generally not seen early in the absence of preoperative fungal infection. In contrast to this case, she had presented as an early fungal PVE without any evidence of preoperative fungal infection. Typically, AE presents with a relative paucity of peripheral signs of endocarditis. The most common clinical features are fever, major peripheral emboli, and a changing heart murmur.[11] Less commonly, patients present with focal or generalized neurologic deficits, heart failure, or dyspnea.[3] However, this patient remained afebrile throughout her primary postsurgical period. She had presented with a short history of breathlessness and diagnosed as acute LVF secondary to a large echogenic mass 2.0 cm × 1.5 cm obstructing the prosthetic repaired mitral valve detected by a transthoracic echocardiography. Initially, the mass was thought to be a thrombus formation, despite the patient being adequately anticoagulated on warfarin with an INR of 3.28. Faced with rapid clinical deterioration of this patient and based on the repeated echocardiography revealing development of severe mitral regurgitation, she was taken for emergency mitral valve replacement. Surgery not only provided therapy for the management of PVE but also provided tissue valve samples for definitive diagnosis through tissue cultures and histopathology. Surgery was the adjunctive tool of definite diagnosis as valve tissue samples were sent for culture and histopathology and has had therapeutic role in the management of PVE. The confirmed diagnosis relies on the evidence from the tissue culture. Surgery as an adjunct to the medical treatment of AE is recommended in all cases with radical debridement of necrotic tissue and valve replacement using biomaterials (bioprosthesis or homografts).[12]

CONCLUSION

In conclusion, AE is a rare clinical entity related usually to a device or prosthesis. A high index of suspicion should be considered in patients with recent cardiothoracic surgery who presented early with acute heart failure. Echocardiographic assessment of suspected AE is critical. Early administration of appropriate antifungal treatment and prompt surgical intervention should improve the prognosis, which remains dismal.
  12 in total

Review 1.  Aspergillus endocarditis after cardiac surgery.

Authors:  Ismaïl El-Hamamsy; Nicolas Dürrleman; Louis-Mathieu Stevens; Louis P Perrault; Michel Carrier
Journal:  Ann Thorac Surg       Date:  2005-07       Impact factor: 4.330

Review 2.  Prosthetic heart valves.

Authors:  W Vongpatanasin; L D Hillis; R A Lange
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

Review 3.  Aspergillus endocarditis: a case of near complete left ventricular outflow obstruction.

Authors:  Rizwan Q Attia; Justin L Nowell; James C Roxburgh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-27

Review 4.  The nature and prevention of prosthetic valve endocarditis.

Authors:  P D Stein; D E Harken; L Dexter
Journal:  Am Heart J       Date:  1966-03       Impact factor: 4.749

5.  Aspergillus fumigatus, a rare cause of fatal coronary artery occlusion.

Authors:  P M Kuijer; E J Kuijper; J G van den Tweel; J van der Lelie
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

Review 6.  Fungal endocarditis: evidence in the world literature, 1965-1995.

Authors:  M E Ellis; H Al-Abdely; A Sandridge; W Greer; W Ventura
Journal:  Clin Infect Dis       Date:  2000-12-12       Impact factor: 9.079

Review 7.  Fungal endocarditis, 1995-2000.

Authors:  Lígia C Pierrotti; Larry M Baddour
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

Review 8.  Fungal endocarditis.

Authors:  E Rubinstein; R Lang
Journal:  Eur Heart J       Date:  1995-04       Impact factor: 29.983

9.  Aspergillus endocarditis after open heart surgery: an epidemiological investigation.

Authors:  G Mehta
Journal:  J Hosp Infect       Date:  1990-04       Impact factor: 3.926

10.  Successful treatment of post-mitral valve annuloplasty Aspergillus flavus endocarditis.

Authors:  D K Wagner; P H Werner; L I Bonchek; T Shimshak; M W Rytel
Journal:  Am J Med       Date:  1985-12       Impact factor: 4.965

View more
  4 in total

1.  Potential benefit of combination antifungal therapy in Aspergillus endocarditis.

Authors:  Kate Lennard; Aiveen Bannan; Peter Grant; Jeffrey Post
Journal:  BMJ Case Rep       Date:  2020-06-11

Review 2.  Aspergillosis of the Heart and Lung and Review of Published Reports on Fungal Endocarditis.

Authors:  Beata Sulik-Tyszka; Piotr Kacprzyk; Krzysztof Mądry; Bogna Ziarkiewicz-Wróblewska; Wiesław Jędrzejczak; Marta Wróblewska
Journal:  Mycopathologia       Date:  2016-05-31       Impact factor: 2.574

3.  Rapid Fulminant Case of Aspergillus Prosthetic Valve Endocarditis.

Authors:  Christian Ortega-Loubon; Manuel Fernández-Molina; Javier Tobar-Ruiz; Nuria Arce-Ramos; Enrique Fulquet-Carreras
Journal:  Cureus       Date:  2017-09-04

4.  Aspergillus flavus endocarditis and meningitis in a child with marfan syndrome.

Authors:  Azam Fattahi; Shirin Sayyahfar; Ensieh Lotfali; Reza Ghasemi; Hojjat Mortezaeian
Journal:  Curr Med Mycol       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.